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Objectives. This study was designed to examine the effects of
denopamine, a selective b1-adrenergic agonist, in a murine model
of congestive heart failure (CHF) due to viral myocarditis.
Background. Positive inotropic agents are used to treat severe
heart failure due to myocarditis. However, sympathomimetic
agents have not been found beneficial in animal models of
myocarditis.
Methods. In vitro: The effects of denopamine on
lipopolysaccharide-induced tumor necrosis factor-a (TNF-a) pro-
duction was studied in murine spleen cells. In vivo: Four-week-old
DBA/2 mice were inoculated with the encephalomyocarditis virus
(day 0). Denopamine (14 mmol/kg), denopamine (14 mmol/kg)
with a selective b1-blocker metoprolol (42 mmol/kg), or denopa-
mine (14 mmol/kg) with metoprolol (84 mmol/kg) was given daily,
and control mice received the vehicle only. Survival and myocar-
dial histology on day 14 and TNF-a levels in the heart on day 6
were examined.
Results. In the in vitro study, TNF-a levels in treated cells were
significantly lower than in controls (p < 0.05). In the in vivo study
treatment with denopamine significantly improved the survival of
the animals (14 of 25 (56%) treated, vs 5 of 25 (20%) control mice),
attenuated myocardial lesions, and suppressed TNF-a production
(66.5 6 7.5 pg/mg of heart in treated mice vs 113.5 6 15.1 pg/mg
of heart in control mice, mean 6 SE). There was a strong linear
relationship between mortality and TNF-a levels (r 5 0.98, n 5 4,
p < 0.05). These in vitro and in vivo effects of denopamine were
significantly inhibited by metoprolol.
Conclusions. These results suggest that denopamine may exert
its beneficial effects, in part, by suppressing the production of
TNF-a via b1-adrenoceptors.
(J Am Coll Cardiol 1998;32:808–15)
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Congestive heart failure (CHF) is the most serious clinical
consequence of viral myocarditis. Furthermore, because viral
myocarditis may lead to dilated cardiomyopathy (1–3), appro-
priate treatment should be administered during the acute
phase of the disease. Positive inotropic agents are regularly
used in the treatment of severe cardiac decompensation due to
myocarditis despite reserved opinions regarding their use in
the treatment of CHF (4,5). Several inotropic agents have been
tested in animals (6), although catecholamines and other
sympathomimetic agents have not been found beneficial in
animal models of myocarditis.
Denopamine, [(2)-a-(3,4-dimethoxyphenethylamino-
methyl)-4-hydroxybenzylalcohol], is an orally active, selective
b1-adrenergic agonist that has no catecholamine moiety in its
chemical structure (7,8). The purpose of this study was to
examine the effects of denopamine on short-term survival of
mice with acute viral myocarditis due to encephalomyocarditis
virus (EMCV) infection (9,10). In addition, because tumor
necrosis factor-a (TNF-a) plays an important role in the
pathophysiology of myocarditis (11–13) and CHF (14–20) the
effects of denopamine on TNF-a production were also mea-
sured.
Methods
Drug preparation. Denopamine was synthesized by
Tanabe Pharmaceutical Co., Ltd. (Osaka, Japan), and meto-
prolol by Sigma Chemical (St Louis, MO, USA). They were
mixed in phosphate buffered saline (PBS) for the purpose of
these experiments.
In vitro studies. Preparation of spleen cells and lipopolysac-
charide stimulation. Spleen cells obtained from 4-week-old
DBA/2 mice were dissociated mechanically by squeezing the
spleen through a mesh screen and cultured in RPMI-FBS on
round-bottomed microplates. Each well contained 3 3 106
spleen cells/mL and the plate was incubated at 37°C in 5% CO2
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with 1 mg/mL lipopolysaccharide (LPS) (Difco Laboratories
Inc., Detroit, MI, USA).
Time course of LPS-induced TNF-a production. After 2, 5,
6, or 22 h of incubation, 0.1 mL samples of supernatant (n 5
3) were obtained from each well for assay of murine TNF-a.
Control samples were not exposed to LPS.
Effect of denopamine on LPS-induced TNF-a production.
Nine quantities each of 0.1, 1, 10, or 100 mmol/L of denopam-
ine were added to each well. The control cultures received the
vehicle only (n 5 9). After 5 h of incubation, 0.1 mL of
supernatant from each well was collected for assay of murine
TNF-a.
Effect of denopamine and metoprolol on LPS-induced
TNF-a production. Denopamine (1 mmol/L), denopamine (1
mmol/L) with metoprolol (1, 5, or 10 mmol/L), or metoprolol
(10 mmol/L) was added to each well (n 5 4). The control
cultures received the vehicle only (n 5 4). After 5 h of
incubation, 0.1 mL of supernatant from each well was collected
for assay of murine TNF-a with a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (Bio-source
International, Camarillo, CA, USA), performed in accordance
with the manufacturer’s instructions. The sensitivity of the kit
is 3 pg/mL.
In vivo studies. Pharmacokinetic study. The pharmacoki-
netics of denopamine after its daily oral administration in a
dose of 14 mmol/kg per day were studied in seven 4-week-old
inbred male DBA/2 mice. After 3 days of treatment, blood was
sampled from the animals’ tails immediately before and 1, 2, 3,
and 5 h after administration of denopamine. Blood was mixed
with 500 mg of ethylenediamine-N,N,N9,N9-tetraacetic acid,
disodium salt, dihydrate (EDTA 3 2 Na) and 500 KIE of
aprotinin solution, and centrifuged to separate the plasma,
which was stored at 280°C. The plasma concentration of
denopamine was measured by liquid chromatography (21).
The sensitivity of the method is 0.6 nmol/L.
Experimental infection. Four-week-old inbred male
DBA/2 mice were inoculated intraperitoneally with 0.1 mL of
the M variant of EMCV diluted in Eagle’s minimal essential
medium to a concentration of 100 plaque-forming units/mL.
The day of virus inoculation was defined as day 0 for the
subsequent studies.
Treatment protocols. Protocol 1: The effects of denopa-
mine were examined against an untreated control group.
Denopamine was administered in a dose of 14 mmol/kg per
day, whereas control mice received the vehicle only. Protocol
2: To test whether the effects of the drug are mediated by
b1-adrenoceptors, the effects of selective b1-blockade on
denopamine were examined in the same experimental model.
Denopamine alone, 14 mmol/kg/day, was administered to 25
mice; 10 mice received denopamine, 14 mmol/kg/day, and
metoprolol, 42 mmol/kg/day, in combination; 20 mice received
denopamine, 14 mmol/kg/day, and metoprolol, 84 mmol/kg/day,
in combination; 25 control mice received the vehicle only.
Survival experiments. Because in this model most mice die
of CHF within 14 days after virus inoculation (9,10) survival
was measured over a 14-day period in this study.
Assay of TNF-a levels in the heart. Because the expression
of TNF-a mRNA in the heart peaked 5 to 7 days after
inoculation (22), the effect of denopamine on TNF-a produc-
tion in the heart was measured on day 7 for protocol 1 and on
day 6 for protocol 2, at which time the surviving animals were
sacrificed by cervical dislocation and their hearts were removed
under sterile conditions. After measurements of the body and
heart weights, the heart was divided in two sections along its
short axis, at the mid left ventricular level. One half was stored
at 280°C, and used for ELISA of TNF-a levels in tissue
homogenates using a modification of the methods described by
Pizarro et al (23), Sekido et al (24), and Torre-Amione et al
(25). Briefly, frozen sections of tissue, suspended in microtubes
with 1.5 mL of phosphate buffered saline solution containing
0.05% NaN3 at 4°C, were ultrasonically homogenized on ice at
50 W (ASTRASONTM Model XL2020, Misnox Inc., Farm-
ingdale, NY, USA), and sonicated for 10 to 20 s (26), while
temperature in the suspension was maintained at 4°C during
homogenization. Heart tissue homogenates were centrifuged
at 14,000 rpm at 4°C for 20 min, and the resultant supernatant
was collected to measure TNF-a levels. Murine TNF-a was
assayed with commercially available ELISA kits (Genzyme
Co., Cambridge, MA, USA) according to the manufacturer’s
instructions. The sensitivity of each kit is 15 pg/mL, respec-
tively. TNF-a levels were expressed as pg/mg of heart.
Histologic examination. The other half of the heart was
used for histologic examination. The specimens were fixed in
10% formalin, embedded in paraffin, sectioned and stained
with hematoxylin and eosin. The extent of cellular infiltration
and myocardial necrosis was graded by two observers blinded
to the treatment assignments, and scored as follows: 0 5 no
lesions; 11 5 lesions involving , 25% of the myocardium;
21 5 lesions involving 25% to 50%; 31 5 lesions involving
50% to 75%; and 41 5 lesions involving 75% to 100%. The
scores assigned by the two observers were averaged.
Statistical analysis. Each value is expressed as mean 6 SE.
Survival was measured by the Kaplan-Meier method, and the
log-rank test was used to determine the significance level.
Statistical comparisons of TNF-a levels, heart weight-to-body
weight (HW/BW) ratios and histologic scores were performed
by Mann-Whitney U-test or Kruskal-Wallis test for in vivo and
in vitro experiments. A simple regression was performed to
verify the linearity of the relationship between the survival rate
and TNF-a levels. A p value ,0.05 was considered statistically
significant.
Abbreviations and Acronyms
CHF 5 congestive heart failure
EMCV 5 encephalomyocarditis virus
TNF-a 5 tumor necrosis factor-a
LPS 5 lipopolysaccharide
ELISA 5 enzyme-linked immunosorbent assay
BW 5 body weight
HW 5 heart weight
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Results
In vitro studies. Time course of LPS-induced TNF-a pro-
duction. Spleen cell TNF-a levels were 69.4 6 5.6 pg/mL at
2 h, 380.6 6 19.4 pg/mL at 5 h, 350.0 6 47.2 pg/mL at 6 h, and
52.8 6 0.2 pg/mL at 22 h of incubation following LPS
stimulation. TNF-a production by spleen cells after LPS
stimulation peaked at 5 h of incubation, whereas in controls it
averaged 11.1 6 0.2 pg/mL over the 22 h period.
Effect of denopamine on LPS-induced TNF-a production.
Denopamine suppressed LPS-induced TNF-a production in a
concentration-dependent manner (Fig. 1A). Compared with a
stimulated control of 510.2 6 87.2 pg/mL, concentrations of
the drug of 0.1, 1, 10 and 100 mmol/L decreased TNF-a levels
by 96.9 6 6.7%, 62.7 6 6.5%, 53.2 6 8.8%, and 40.3 6 1.5%,
respectively (n 5 9 each). At the 3 highest drug concentrations
(1, 10, and 100 mmol/L), TNF-a levels were significantly lower
than in the control culture stimulated by LPS (p , 0.05).
Effect of denopamine and metoprolol on LPS-induced
TNF-a production. Denopamine (1 mmol/L) suppressed LPS-
induced TNF-a production, whereas metoprolol blocked that
suppression in a concentration-dependent manner (Fig. 1B).
Compared with a stimulated control of 242.1 6 43.1 pg/mL,
denopamine alone, in a concentration of 1 mmol/L decreased
TNF-a levels by 50.6 6 5.9% (p , 0.05 vs control). Addition of
metoprolol in increasing concentrations of 1, 5, and 10 mmol/L
increased the TNF-a levels compared to denopamine alone by
64.2 6 3.1%, 76.0 6 8.0%, and 96.6 6 9.1%, respectively (n 5
4 each). At the highest drug concentration of metoprolol (10
mmol/L), TNF-a levels were significantly higher than in the
denopamine alone culture stimulated by LPS (p , 0.05) and
comparable to values measured in controls.
In vivo study. Pharmacokinetic study. The plasma concen-
tration of denopamine was 13.1 6 1.9 nmol/L at 1 h, 4.3 6 0.9
nmol/L at 2 h, 1.8 6 0.5 nmol/L at 3 h, and ,0.6 nmol/L at 5 h
after its administration. A single 14 mmol/kg dose of denopam-
ine in mice produced a peak level at 1 h. The peak plasma
concentration was comparable to that achieved with a single,
oral 10 mg daily dose associated with therapeutic efficacy in
humans (27). The half-life of the drug in plasma was 0.71 h.
Protocol 1. At day 14, the survival rate of 57.1% (16 of 28
mice) in the denopamine group was significantly higher than
the 33.3% (10 of 30 mice) survival rate in the control group
(p , 0.05, Fig 2A). The survival rate from day 6 to day 14 was
also significantly improved in the denopamine group (69.6%;
16 of 23 mice) versus the control group (45.5%; 10 of 22 mice,
p , 0.05). By day 7, compared with an infected control of
1,258.5 6 247.0 pg/mg of heart (n 5 11), denopamine, in a
concentration of 14 mmol/kg, had decreased TNF-a levels by
58.5 6 6.6% (p , 0.05 vs control, n 5 17). This statistically
significant difference was found in the absence of a significant
difference in heart weight-to-body weight ratio (HW/BW) ratio
on day 7 (Table 1) between the treated group (7.8 6 0.3 3
Figure 1. (A) Effect of increasing concentrations of denopamine on
1 mg/mL LPS-induced TNF-a production in murine spleen cells.
LPS-induced TNF-a production was suppressed by denopamine in a
concentration-dependent manner. Values are means 6 SE of 9
cultures. *p , 0.05 versus the control culture stimulated by LPS. (B)
Effect of denopamine and metoprolol on 1 mg/mL LPS-induced
TNF-a production in murine spleen cells. LPS-induced TNF-a pro-
duction was significantly suppressed by denopamine, 1 mmol/L. Meto-
prolol blocked the suppression of TNF-a production in a
concentration-dependent manner. Values are means 6 SE of 4
cultures. *p , 0.05 versus the control stimulated by LPS, denopamine
with metoprolol concentration of 10 mmol/L, or metoprolol alone (10
mmol/L).
Figure 2. (A) Significant improvement by denopamine in survival of
mice to day 14 after EMCV inoculation. E 5 control group (n 5 30);
} 5 14 mmol/kg denopamine treatment group (n 5 28). *p , 0.05 (B)
Effect of denopamine on TNF-a levels in the heart on day 7 and day
14. TNF-a in the hearts of mice treated with denopamine (n 5 17 on
day 7; n 5 7 on day 14) was significantly lower than in those of control
animals (n 5 11 on day 7; n 5 6 on day 14). Solid bars 5 day 7; clear
bars 5 day 14. Values are means 6 SE. *p , 0.05 versus control group.
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1023, n 5 17) and the control group (8.5 6 0.5 3 1023, n 5
11). Likewise, no significant differences were found between
the two groups in histologic scores for cellular infiltration
(1.9 6 0.2, n 5 17 in the treated group versus 1.7 6 0.2, n 5
11 in the control group) or in the scores for myocardial
necrosis (1.9 6 0.2 versus 2.0 6 0.3, Table 1). The effects of
denopamine on TNF-a levels in the heart and myocardial
histology at day 14 were examined in separate experiments.
Compared with an infected control of 43.5 6 11.3 pg/mg of
heart (n 5 6), denopamine significantly decreased TNF-a
levels by 54.5 6 6.2% (p , 0.05 vs control, n 5 7, Fig 2B). In
contrast to day 7, a significant difference in HW/BW ratio was
found on day 14 (Table 2) between the treated group (5.5 6
0.2 3 1023, n 5 7, p , 0.05) and the control group (6.6 6 0.4 3
1023, n 5 6). Likewise, significant differences were found
between the two groups in histologic scores for cellular infil-
tration (1.4 6 0.2, n 5 7 in the treated group vs 2.3 6 0.2, n 5
6 in the control group, p , 0.05) and in the scores for
myocardial necrosis (1.1 6 0.3 vs 2.0 6 0.3, p , 0.05, Table 2
and Fig. 3).
Protocol 2. At day 14, the survival rates were 56% (14 of 25
mice) in the group treated with denopamine alone, 40% (4 of
10 mice) in the group treated with denopamine (14 mmol/kg)
and metoprolol (42 mmol/kg), 25% (5 of 20 mice) in the group
treated with denopamine (14 mmol/kg) and metoprolol (84
mmol/kg), and 20% (5 of 25 mice) in the control group (Fig.
4A). The survival rate was significantly higher in the
denopamine-alone-treated group than in either the group
treated with denopamine (14 mmol/kg) and high-dose meto-
prolol (84 mmol/kg) or the control group (p , 0.05).
No statistically significant differences were found among the
four groups in the HW/BW ratio, histologic scores for cellular
infiltration or in the scores for myocardial necrosis (Table 3).
The HW/BW ratio was 8.5 6 0.4 3 1023 in the group treated
with denopamine alone, 9.0 6 0.7 3 1023 in the denopamine
with low-dose metoprolol group, 9.1 6 0.2 3 1023 in the
denopamine with high-dose metoprolol group and 8.8 6 0.2 3
1023 in the control group (n 5 5 each). Histologic scores for
cellular infiltration were 2.6 6 0.4, 2.8 6 0.2, 2.8 6 0.2, and
2.6 6 0.2, respectively, and those for myocardial necrosis were
2.6 6 0.4, 2.8 6 0.2, 3.0 6 0.3, and 2.8 6 0.4, respectively (n 5
5 each).
At day 6, denopamine alone suppressed TNF-a levels in the
heart and metoprolol reversed the suppression of TNF-a
production in a concentration-dependent manner (Fig. 4B).
Compared with a control value of 113.5 6 15.1 pg/mg of heart,
denopamine alone, in a concentration of 14 mmol/kg, de-
creased TNF-a levels by 58.5 6 6.6% (p , 0.05 vs control).
Addition of metoprolol in concentrations of 42 and 84 mmol/kg
increased the TNF-a levels by 73.3 6 15.3% and 91.9 6 12.1%,
respectively (n 5 5 each), compared to denopamine alone. At
the highest concentration of metoprolol (84 mmol/L), TNF-a
levels were significantly higher than in the denopamine alone
group (p , 0.05, Fig 4B).
The relation between TNF-a levels in the heart on day 6
and mortality from day 6 to day 14. Mortality from day 6 to
day 14 was 33.3% (7 of 21 mice) in the group treated with
denopamine alone, 50% (4 of 8 mice) in the group treated with
denopamine and low-dose metoprolol, 68.8% (11 of 16 mice)
in the group treated with denopamine and high-dose metopro-
lol, and 73.7% (14 of 19 mice) in the control group (Table 4).
Figure 3. Effects of denopamine on histopathologic changes at day 14.
Myocardial lesions in mice treated with denopamine were significantly
less than in control animals. (A) control animals. (B) denopamine-
treated animals. Hematoxylin-eosin stain; original magnification: 312.
Table 1. Effects of Denopamine on HW/BW and Myocardial




Control 11 8.5 6 0.5 1.7 6 0.2 2.0 6 0.3
Denopamine 14 mg/kg 17 7.8 6 0.3 1.9 6 0.2 1.9 6 0.2
HW/BW 5 heart weight-to-body weight ratio. Values are means 6 SE. The
differences between the 2 groups are not statistically significant.
Table 2. Effects of Denopamine on HW/BW and Myocardial




Control 6 6.6 6 0.4 2.3 6 0.2 2.0 6 0.3
Denopamine 14 mg/kg 7 5.5 6 0.2* 1.4 6 0.2* 1.1 6 0.3*
HW/BW 5 heart weight-to-body weight ratio. p , 0.05 vs control. Values are
means 6 SE.
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A significant linear relationship was found (Fig. 5) between
second week mortality and TNF-a levels in the heart measured
on day 6 (R 5 0.98, n 5 4, p , 0.05). The same strong
relationship (R 5 0.98, n 5 4, p , 0.05) was observed on day
14.
Discussion
The goals of heart failure management are to improve
quality of life and increase patient survival. Although positive
inotropic agents have favorable initial hemodynamic effects
and offer symptomatic relief in heart failure patients, their
impact on survival has been disappointing (5,28). These drugs
are divided into three main groups: digitalis glycosides, phos-
phodiesterase inhibitors, and sympathomimetic amines. Digi-
talis glycosides, which increase sodium intracellular concentra-
tions by inhibiting sodium-potassium ATPase (29), have
occupied a prominent place in the management of CHF, but
their clinical use is limited by a narrow therapeutic window
(30). Phosphodiesterase inhibitors, which increase intracellular
cyclic AMP by inhibiting phosphodiesterase III, are in the
spotlight as new inotropic agents (31), although their efficacy
has not been firmly established (32). Catecholamines and other
sympathomimetic amines, which increase intracellular cyclic
AMP by stimulating b-adrenergic receptors, have been used
for many years to treat severe CHF. However, their use is
limited by various undesirable chronotropic, vasoconstrictor or
vasodilator, and arrhythmogenic effects (33,34). It has also
been suggested that increased intracellular concentration of
cyclic AMP, by stimulating the b-adrenergic receptors, may
accelerate the rate of cell death, and that calcium overload may
induce arrhythmias and myocardial injury (35,36). Further-
more, clinical trials have observed an increase in mortality
associated with their long-term use (37).
General properties of denopamine. Denopamine was de-
veloped and synthesized in the hope of eliminating or reducing
Figure 4. (A) Effects of denopamine and metoprolol on survival of
mice to day 14 after EMCV inoculation. Denopamine significantly
improved the survival; the effect was significantly blocked by metopro-
lol at a concentration of 84 mmol/kg. E 5 control group (n 5 25); h 5
denopamine, 14 mmol/kg 1 metoprolol, 84 mmol/kg treatment group
(n 5 20);  5 denopamine, 14 mmol/kg 1 metoprolol, 42 mmol/kg
treatment group (n 5 10); } 5 denopamine alone, 14 mmol/kg
treatment group (n 5 25). *p , 0.05 versus control, or versus
denopamine, 14 mmol/kg 1 metoprolol, 84 mmol/kg treatment group.
(B) Effect of denopamine and metoprolol on TNF-a levels in the heart
on day 6. TNF-a in the hearts of mice treated with denopamine was
significantly lower than in those of control animals. The effect of
denopamine was significantly blocked by metoprolol at a concentration
of 84 mmol/kg. Values are means 6 SE. N 5 5 in each group. Deno 5
denopamine, 14 mmol/kg; low Meto 5 metoprolol, 42 mmol/kg; high
Meto 5 metoprolol, 84 mmol/kg. *p , 0.05 versus control or 14
mmol/kg denopamine with 84 mmol/kg metoprolol treatment group.
Figure 5. Significant, linear relationship between mortality from day 6
to day 14 and TNF-a levels measured on day 6 (R 5 0.98, n 5 4, p ,
0.05).
Table 3. Effects of Denopamine and Metoprolol on HW/BW and




Control 5 8.8 6 0.2 2.6 6 0.2 2.8 6 0.4
Deno 1 high Meto 5 9.1 6 0.2 2.8 6 0.2 3.0 6 0.3
Deno 1 low Meto 5 9.0 6 0.7 2.8 6 0.2 2.8 6 0.2
Deno 5 8.5 6 0.4 2.6 6 0.4 2.6 6 0.4
HW/BW 5 heart weight-to-body weight ratio; high Meto 5 metoprolol
84 mg/kg; low Meto 5 metoprolol 42 mg/kg; Deno 5 denopamine 14 mg/kg;
Values are means 6 SE. The differences among the 4 groups are not statistically
significant.
Table 4. Mortality from Day 7 to Day 14
Number of Survivors
MortalityDay 6 Day 14
Control 19 5 73.7%
Deno 1 high Meto 16 5 68.8%
Deno 1 low Meto 8 4 50.0%
Deno 21 14 33.3%*
High Meto 5 metoprolol 84 mg/kg; low Meto 5 metoprolol 42 mg/kg;
Deno 5 denopamine 14 mg/kg
*p , 0.05 vs control or Deno 1 high Meto. Values are means 6 SE.
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these limitations. In Japan, the drug has been used in approx-
imately 60,000 patients since 1988, and several reports have
confirmed its efficacy in the treatment of chronic CHF (27,38–
40). Denopamine has little effect on heart rate (41) and is less
proarrhythmic than ouabain or isoproterenol (42). Minimal or
no changes have been measured in left ventricular systolic
pressure and myocardial oxygen consumption (43). Tolerance
of b-adrenergic receptors to its inotropic action has not been
observed after its administration for 14 days (44). In addition,
denopamine causes peripheral vascular smooth muscle relax-
ation mediated by the blocking effect of a1-adrenoceptors (45).
Denopamine, cytokine production, and beta adrenergic
receptors. Several studies have shown an integration of neu-
roendocrine hormones into the immune response. Adrenergic
agents, in particular, have been shown to influence cytokine
production (46–50). Similarly, the present study found that
denopamine directly suppressed LPS-induced TNF-a produc-
tion from murine spleen cells. In splenic tissue, TNF-a is
mainly synthesized by macrophages and lymphocytes (51).
Agents that act via b1-adrenoceptors inhibit LPS-induced
TNF-a production from the promonocytic leukemia cell line
THP-1 by increasing intracellular cyclic AMP levels (46). On
the other hand, lymphocytes have b2- but no b1-adrenergic
receptors (52). Because denopamine does not increase cyclic
AMP via b2-adrenergic receptors even in a dose of 100 mmol/L
(7), it probably does not act on lymphocytes through their
b2-receptors. To determine whether the effect of denopamine
on TNF-a was mediated by b1-adrenoceptors, the selective
b1-antagonist metoprolol was administered with denopamine
(53). Metoprolol significantly blocked the effect of denopa-
mine. Thus, it is suggested that denopamine inhibits LPS-
induced TNF-a production by macrophages via b1-
adrenoceptors in murine spleen cells.
The present study also showed that denopamine inhibited
TNF-a production in the heart. In our murine model of viral
myocarditis, immunohistochemical studies showed that TNF-a
immunostaining in the heart was localized to macrophages,
lymphocytes, and endothelial cells (22). To date, no report has
described the effects of b-adrenergic agonists on TNF-a pro-
duction by endothelial cells. We also examined the effects of
denopamine combined with metoprolol in our model and
found that metoprolol is able to block the action of denopa-
mine in vitro and in vivo. As discussed above, the effect of
denopamine on TNF-a production in heart tissue homoge-
nates is probably due to inhibition of TNF-a production by
macrophages through b1-adrenoceptors.
Effects of denopamine on short-term survival. Denopa-
mine prolonged the survival of mice during the acute stage of
viral myocarditis. In our animal model of CHF due to viral
myocarditis, myocardial necrosis and mononuclear cellular
infiltration appear 4 to 5 days after viral inoculation, with some
mice dying as early as day 5, and others developing severe CHF
after day 7 (9,10). Denopamine significantly improved survival
rates past day 7, despite no significant improvement in the
extent of myocardial injury on day 6 or 7. In contrast, deno-
pamine significantly attenuated myocardial lesions on day 14.
Thus, it exerted its primary effect at a stage when the majority
of deaths were caused by CHF. Recent reports have empha-
sized the importance of cytokines, TNF-a in particular, in the
pathophysiology of CHF (14–20). Severe CHF was caused in
transgenic mice with myocardial expression of TNF-a (19) and
the infusion of TNF-a led left ventricular dysfunction and
remodeling in the experimental model (20). Circulating levels
of TNF-a are increased in patients with CHF (25,54–57) and
its direct and indirect negative inotropic effects have been
described (57–59). These observations lead us to hypothesize
that TNF-a is one of the factors that exacerbate heart failure
in its acute phase. In this study, denopamine suppressed
TNF-a production in vitro and in vivo. These findings suggest
that denopamine may improve inotropy, attenuate myocardial
damage, and prolong survival in CHF due to viral myocarditis
by inhibiting TNF-a, a hypothesis supported by the significant
linear relationship that was found between second-week mor-
tality and TNF-a levels in the heart. Because most cytokines
act in an autocrine or paracrine manner, circulating levels of
cytokines may not accurately reflect their effects on target
organs (15). Furthermore, there is no significant correlation
between the level of TNF-a in the myocardium and its level in
plasma, probably because of its multiple sites of production in
CHF (25). For this reason, TNF-a levels in this study were
measured in heart tissue homogenates and a correlation was
found between the level of TNF-a in the heart and the
prognosis of CHF in its acute phase.
Denopamine treatment and myocardial injury. Studies
from several laboratories have shown that TNF-a exacerbates
myocardial injury (11–13). In this study, the extent of myocar-
dial damage was not attenuated in the denopamine-treated
group on day 6 or 7, despite the inhibition of TNF-a produc-
tion in the heart, an observation that seems to contradict these
other reports. However, we have reported that anti-TNF-a
antibody treatment attenuated myocardial lesions in the same
murine model if the onset of treatment is postponed until day
1 and administered between day 1 and day 4, instead of
between day 0 and day 4 (12). In this study denopamine
treatment was started on day 0 until day 14. Thus, myocardial
lesions may not have been attenuated on day 6 or 7, despite
inhibition of TNF-a production. In contrast, denopamine did
attenuate the extent of myocardial lesions and inhibited
TNF-a production at day 14. Past day 7, at the stage of CHF,
it exerted its protective effects through its inhibitory action on
TNF-a production.
Conclusions. Denopamine prolonged survival, attenuated
myocardial lesions, and inhibited TNF-a production in a
murine model of CHF induced by viral myocarditis. These
results suggest that denopamine may exert its beneficial effects
partially through the suppression of TNF-a production.
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